Resumen

RIVERA-SANCHEZ, Roberto et al. Utilidad del antígeno prostático específico total y del índice de antígeno prostático específico libre para detectar cáncer de próstata en el paciente asintomático. Acta bioquím. clín. latinoam. [online]. 2022, vol.56, n.1, pp.11-15. ISSN 0325-2957.

Circulating prostate-specific antigen (PSA) is bound to alpha-1-chymotrypsin and a small fraction is free (PSAl). The clinical utility of the total PSA (PSAt) and the PSAl index for prostate cancer screening in asymptomatic patients was assessed. PSAt, PSAl and the PSAl index were quantified in 364 patients stratified by age group. The frequency of abnormal PSAt values was 8.79% (32/364). The 50-59 year-old group presented the highest incidence of abnormal results (19/32). There was no statistically significant difference between PSAt and the PSAl index (p<0.05). The PSAl index can potentiate the PSAt value to determine the presence or absence of prostate cancer. An index greater than 0.24 ng/mL can help to avoid or postpone the indication for a biopsy, especially when the PSAt values are between 4 and 10 ng/mL.

Palabras clave : Prostate specific antigen; Serine protease; Free prostate antigen; Prostate cancer; Benign prostatic hypertrophy.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )